Allozyne is a technology company.
Allozyne has raised $34.0M across 2 funding rounds.
Allozyne has raised $34.0M in total across 2 funding rounds.
Allozyne has raised $34.0M in total across 2 funding rounds.
Allozyne's investors include ARCH Venture Partners.
Allozyne was a clinical-stage biotechnology company that developed protein optimization technologies to create improved biologics for chronic diseases like multiple sclerosis (MS) and Crohn's disease.[1][2] Its lead product, AZ01 (a long-acting peginterferon beta), targeted relapsing-remitting MS by enhancing efficacy, tolerability, and pharmacology through site-specific incorporation of amino acid analogs into proteins.[1][5] The company served patients with central nervous system and autoimmune disorders, addressing unmet needs in protein-based therapeutics like interferons and antibody-drug conjugates (ADCs) via proprietary platforms Caesar and Vigenère, which enabled homogeneous, stable modifications for better dosing and safety.[1][2][3] Founded in 2005 and headquartered in Seattle, Allozyne raised about $40-50 million before being acquired by MedImmune in 2014 for its ADC technology, marking the end of its independent operations.[1][2]
Allozyne was founded in 2005 by researchers from the California Institute of Technology (Caltech): William A. Goddard III, David A. Tirrell, and Dee (Deepshikha) Datta, PhD, who developed the core biociphering technology during post-doctoral work at Caltech's Materials and Process Simulation Center.[1][2] Incubated by Accelerator Corporation, it launched with $50 million from investors including MPM Capital, OVP Venture Partners, and ARCH Venture Partners, focusing initially on methionine analogs in recombinant interferon beta for MS.[1][2] Early traction came from advancing AZ01 into clinical stages and expanding platforms to ADCs and other protein therapeutics, culminating in the 2014 acquisition by MedImmune, which valued its homogeneous conjugation methods for toxins to antibodies.[1]
Allozyne rode the early 2000s biotech wave in protein engineering and precision medicine, capitalizing on advances in synthetic biology to refine biologics amid rising demand for MS and autoimmune treatments.[1][2] Its timing aligned with growing recognition of limitations in first-generation biologics—like inconsistent conjugation in ADCs—positioning its homogeneous platforms as a market force for more predictable, potent therapies.[1][4] By influencing ADC development, Allozyne contributed to the ecosystem's shift toward site-specific modifications, paving the way for subsequent innovations in biologics that MedImmune (and AstraZeneca) leveraged post-acquisition.[1] This helped Seattle's biotech corridor emerge as a hub, amplifying investor interest in protein optimization tools.[1]
Allozyne's legacy endures through its ADC technology integrated into MedImmune/AstraZeneca's pipeline, potentially fueling ongoing advancements in homogeneous conjugates for oncology and autoimmune diseases.[1] Post-2014, trends like AI-driven protein design and expanded biologics manufacturing could amplify its foundational methods, evolving their influence in next-gen therapeutics. As biotech consolidates around precision engineering, Allozyne exemplifies how targeted protein tweaks can drive acquisition value and shape enduring solutions for unmet medical needs.[1][2]
Allozyne has raised $34.0M across 2 funding rounds. Most recently, it raised $30.0M Series B in October 2007.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2007 | $30.0M Series B | ARCH Venture Partners | |
| Dec 1, 2005 | $4.0M Series A | ARCH Venture Partners |